Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 215 results found. Search for [ pharma major Lupin ]

Results 40 to 60 of 215
PB Jayakumar
New Delhi, April 15, 2020
How healthcare, FMCG, pharma, petrochemical and IT companies will turn the capabilities acquired during the coronavirus crisis into new businesses in India and abroad


BusinessToday.In
April 9, 2020
Sensex, Nifty Live News Today: Globally indices turned green as investors turned optimistic over prospects of more government stimulus and tightened lockdowns across the world to combat the virus spread.


PB Jayakumar | E Kumar Sharma
April 7, 2020
According to some studies, Hydroxychloroquine has shown strong antiviral effects on the coronavirus infection, which prompted US President Donald Trump to seek India's help in procuring the drug


BusinessToday.In
April 7, 2020
Sensex, Nifty Live News Today: All 30 Sensex and 50 Nifty stocks closed higher today. Over 14 out of 30 Sensex stocks and almost 21 Nifty stocks were gaining over 10% at the closing bell.  


BusinessToday.In
April 6, 2020
Stocks to watch today on April 7: HDFC Bank, Lupin, Kotak Mahindra Bank, IndusInd Bank, Sobha, DCB Bank, MOIL, NMDC, Force Motors, Dhampur Sugar Mills, Bharat Gears, Axis Bank, ICICI Bank among others are the top stocks to watch out for in Tuesday's trading session


BusinessToday.In
April 3, 2020
Sensex, Nifty Live News Today:The 30-share index BSE Sensex fell 700 points lower at 27,550 and 50-share barometer NSE Nifty fell 176 points to 8,076.


Rupa Burman Roy
March 31, 2020
CLSA also upgraded Lupin from Sell to Outperform with a revised target price to Rs 660 from Rs 600 earlier.


BusinessToday.In
March 31, 2020
 Sensex, Nifty Live News Today: Sensex ended 1,028 points higher at 29,468 and Nifty closed 316 points to trade at 8,597


BusinessToday.In
March 30, 2020
Sensex, Nifty Live News Today: BSE 30-share barometer Sensex ended 1,375 points lower at 28,440 and NSE 50-share index Nifty fell 379 points to close at 8,281.


BusinessToday.In
March 26, 2020
Stocks to watch today on March 27: Laurus Labs, Wabco India, Sonata Software, Sanghvi Movers, Lupin, Mindtree, Motilal Oswal among others are the top stocks to watch out for in Friday's trading session


BusinessToday.In
March 17, 2020
Share Market LIVE Updates: Where Sensex ended 810 points lower to 30,579, Nifty closed 229 points to trade at 8,968 mark.


BusinessToday.In
March 9, 2020
Stocks to watch today on March 11: Asian Paints, Cadila, Lupin, City Union Bank among others are the top stocks to watch out for in Wednesday's trading session


BusinessToday.In
March 5, 2020
Stocks to watch today on March 6: YES Bank, Tata Power, Cadila, Lupin, PNB, Union Bank among others are the top stocks to watch out for in Friday's trading session


BusinessToday.In
February 17, 2020
Coronavirus in China: Hubei in China is a major supplier of the raw material- API used in several medical formulations. In order to decide a course of action, the government is likely to consult an 8-member panel


E Kumar Sharma
New Delhi, January 30, 2020
Coronavirus outbreak is likely to disrupt supplies of drug ingredients for Indian pharma manufacturers, mostly antibiotics and vitamin makers


BusinessToday.In
January 20, 2020
Share Market Update: BSE Sensex ended 400 points lower at 41,528 and NSE Nifty traded 121 points lower at 12,230 by the closing bell.


PB Jayakumar
January 16, 2020
Wockhardt latest medicines: Wockhardt announces two new drugs for skin infections, its shares rise by 14 per cent intraday. Here's what this means


BusinessToday.In
January 13, 2020
Share Market Update: Infosys was the top gainer today, rising 4% on NSE. On the other hand, YES Bank was the top loser today with shares of the lender declining over 8%


BusinessToday.In
December 17, 2019
Share Market Update: Sensex rose to its lifetime high of 41,401 in Tuesday's trade, NSE Nifty cliamed a all-time high of 12,182 today


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


PAGES 3 OF 11  12345